Elan has signed a licensing agreement with US drug company Bristol Myers Squibb for its NanoCrystal drug delivery system.
NanoCrystal technology enhances the performance of poorly water-soluble drugs by transforming them into minute particles which can then be ingested by patients.
Today's licensing deal provides Bristol-Myers Squibb with access to NanoCrystal technology and the right to develop and commercialise products incorporating this technology.
